| Product Code: ETC8853897 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Pharmacological management of urinary retention includes alpha-blockers and anticholinergics. The market is closely linked with prostate health and neurological disorders. Urban centers lead in prescription rates due to better specialist access and higher diagnosis rates.
Pharmacological treatment for urinary retention, such as alpha-blockers and cholinergic drugs, is experiencing growth in the country. This trend is influenced by a rising number of patients with benign prostatic hyperplasia (BPH) and neurological disorders. Physicians are favoring drug-based therapies over surgical interventions, especially for mild to moderate cases.
Urinary retention drugs face limited usage because many cases are still managed through catheterization or surgical options rather than long-term pharmacological treatment. The lack of public health campaigns and delayed diagnosis contribute to under-treatment. Furthermore, limited availability of advanced drug formulations and concerns over side effects also hamper growth.
The demand for medications addressing urinary retention is expanding alongside urology consultations. Investors can explore licensing of anticholinergics or combination therapies. Partnering with urologists and distributing through hospitals and pharmacies is essential.
Treatment drugs for urinary retention, such as alpha-blockers or cholinergic agents, are approved by the FDA and included in the Philippine National Drug Formulary. These are available through both public and private hospitals and are partially reimbursed by PhilHealth. The DOH promotes proper prescribing through continuing medical education programs.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Urinary Retention Drugs Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Urinary Retention Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Urinary Retention Drugs Market - Industry Life Cycle |
3.4 Philippines Urinary Retention Drugs Market - Porter's Five Forces |
3.5 Philippines Urinary Retention Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Philippines Urinary Retention Drugs Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Philippines Urinary Retention Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Urinary Retention Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of urinary retention disorders in the Philippines |
4.2.2 Rising awareness about the availability and benefits of urinary retention drugs |
4.2.3 Growing geriatric population in the country |
4.3 Market Restraints |
4.3.1 Stringent regulatory processes for drug approval in the Philippines |
4.3.2 Limited access to advanced medical facilities in rural areas of the country |
5 Philippines Urinary Retention Drugs Market Trends |
6 Philippines Urinary Retention Drugs Market, By Types |
6.1 Philippines Urinary Retention Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Philippines Urinary Retention Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Philippines Urinary Retention Drugs Market Revenues & Volume, By Alpha Blockers, 2021- 2031F |
6.1.4 Philippines Urinary Retention Drugs Market Revenues & Volume, By Alpha Reductase Inhibitors, 2021- 2031F |
6.1.5 Philippines Urinary Retention Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Philippines Urinary Retention Drugs Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Philippines Urinary Retention Drugs Market Revenues & Volume, By Acute Urinary Retention, 2021- 2031F |
6.2.3 Philippines Urinary Retention Drugs Market Revenues & Volume, By Chronic Urinary Retention, 2021- 2031F |
6.3 Philippines Urinary Retention Drugs Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Philippines Urinary Retention Drugs Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.3.3 Philippines Urinary Retention Drugs Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.3.4 Philippines Urinary Retention Drugs Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 Philippines Urinary Retention Drugs Market Import-Export Trade Statistics |
7.1 Philippines Urinary Retention Drugs Market Export to Major Countries |
7.2 Philippines Urinary Retention Drugs Market Imports from Major Countries |
8 Philippines Urinary Retention Drugs Market Key Performance Indicators |
8.1 Number of prescriptions for urinary retention drugs |
8.2 Patient adherence rate to prescribed medications |
8.3 Number of healthcare facilities offering urinary retention treatments |
9 Philippines Urinary Retention Drugs Market - Opportunity Assessment |
9.1 Philippines Urinary Retention Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Philippines Urinary Retention Drugs Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Philippines Urinary Retention Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Urinary Retention Drugs Market - Competitive Landscape |
10.1 Philippines Urinary Retention Drugs Market Revenue Share, By Companies, 2024 |
10.2 Philippines Urinary Retention Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |